Basiliximab adverse effects

Basiliximab is contraindicated in patients with known hypersensitivity to this antibody. There is a slightly increased risk of GI discomfort compared with placebo after treatment with basiliximab. However, there is no difference in the incidence of malignancies and infections between patients receiving basiliximab versus placebo. Furthermore, it does not increase the adverse effects resulting from the administration of a standard immunosuppressive regimen and other medications. 

Compared with placebo, basiliximab was not associated with any specific adverse effects in early studies (3). However, severe h)rpersensitivity reactions can occur and can be associated with the cytokine release syndrome. 

A 42-year-old Hispanic woman, with end-stage renal disease, anemia, hypertension, and a history of an anaphylactic reaction to basiliximab, was scheduled to receive a living donor transplant and received basiliximab uneventfully (5). However, owing to donor infection the procedure was cancelled and rescheduled for 2 weeks later. Within 10 minutes after basiliximab reinduction she developed an anaphylactic reaction. In an attempt to find another induction therapy for this patient, skin testing was performed for daclizumab without response. She therefore received full-dose induction with daclizumab before her organ transplant without adverse effect. 

Few adverse effects have been reported with basiliximab and daclizumab (see Table 87-4). In clinical trials, these drugs were asso-... 

The concurrent use of basiliximab with azathioprine, muromon-ab-CD3 or mycophenolate is not associated with an increase in adverse effects or infections. The dose requirements of ciclosporin or tacrolimus may be altered by basiliximab. Basiliximab is reported not to interact with analgesics, anti-infective drugs, diuretics, beta blockers or calcium-channel blockers. 

Azathioprine, added to regimens ineluding basiliximab, eielosporin microemulsion and corticosteroids reduced the clearance of basiliximab by 22%. However, the use of basiliximab in triple regimens with azathioprine did not increase adverse effects or infections. ... 

---

See also in sourсe #XX -- [ ]

See also in sourсe #XX -- [ ]

See also in sourсe #XX -- [ ]

---